Back to mobile site

UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

October 20, 2025 9:22 AM EDT Send to a Friend
UBS analyst David Dai reiterated a Buy rating and $30.00 price target on Summit ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login